Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Prostate cancer treatment: the times they are a' changin'.

Kirby R, Challacombe B, Dasgupta P, Fitzpatrick JM.

BJU Int. 2012 Nov;110(10):1408-11. doi: 10.1111/j.1464-410X.2012.11441.x. Epub 2012 Sep 3. Review. No abstract available.

2.

[New hope in the treatment of advanced cancer of the prostate in 2012].

Massard C.

Bull Cancer. 2012 Jul;99 Suppl 1:S3. French. No abstract available.

PMID:
23767051
3.

[The trend toward development of novel agents based on the mechanism of prostate cancer progression].

Iwasaki K, Obara W, Fujioka T.

Nihon Rinsho. 2011 Jun;69 Suppl 5:150-4. Review. Japanese. No abstract available.

PMID:
22207961
4.

New treatment options for patients with metastatic prostate cancer.

Snoeks LL, Ogilvie AC, van Haarst EP, Siegert CE.

Neth J Med. 2013 Jul-Aug;71(6):290-4. Review.

5.

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.

J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

PMID:
22956807
6.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Tanimoto T, Hori A, Kami M.

N Engl J Med. 2010 Nov 11;363(20):1966; author reply 1967-8. doi: 10.1056/NEJMc1009982#SA1. No abstract available.

PMID:
21067392
7.

[Strategy in advanced castration-resistant prostate cancer].

Gross-Goupil M, Roca S, Pasticier G, Ravaud A.

Bull Cancer. 2012 Jul;99 Suppl 1:S37-45. doi: 10.1684/bdc.2012.1562. Review. French.

PMID:
22522582
8.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Nabhan C.

N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi: 10.1056/NEJMc1009982#SA2. No abstract available.

PMID:
21067391
9.

Novel molecular targets for the therapy of castration-resistant prostate cancer.

Agarwal N, Sonpavde G, Sternberg CN.

Eur Urol. 2012 May;61(5):950-60. doi: 10.1016/j.eururo.2011.12.028. Epub 2011 Dec 22. Review.

PMID:
22209376
10.

New treatments for metastic prostate cancer.

[No authors listed]

Med Lett Drugs Ther. 2010 Sep 6;52(1346):69-70.

PMID:
20814400
11.

Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.

Crawford ED, Flaig TW.

Oncology (Williston Park). 2012 Jan;26(1):70-7. Review.

12.

Advanced clinical states in prostate cancer.

Cheng HH, Lin DW, Yu EY.

Urol Clin North Am. 2012 Nov;39(4):561-71. doi: 10.1016/j.ucl.2012.07.011. Epub 2012 Sep 12. Review.

PMID:
23084531
13.

[Castration resistant prostate cancer 2011].

Miller K.

Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24. Review. German.

PMID:
21437832
14.

[Promising on advanced cancer, several new drugs coming].

Widmark A, Karlsson CT.

Lakartidningen. 2012 Feb 22-28;109(8):416-9. Review. Swedish. No abstract available.

PMID:
22509668
15.

New treatment options for castration-resistant prostate cancer.

Simondsen K, Kolesar J.

Am J Health Syst Pharm. 2013 May 15;70(10):856-65. doi: 10.2146/ajhp110586. Review.

PMID:
23640346
16.

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators.

Eur J Cancer. 2013 Nov;49(17):3648-57. doi: 10.1016/j.ejca.2013.07.144. Epub 2013 Aug 22.

PMID:
23973186
17.

Cabazitaxel in prostate cancer: stretching a string.

Dorff TB, Quinn DI.

Lancet. 2010 Oct 2;376(9747):1119-20. doi: 10.1016/S0140-6736(10)61510-3. No abstract available.

PMID:
20888974
18.

[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].

Boissier E, Loriot Y, Vignot S, Massard C.

Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French.

PMID:
24793632
20.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

Supplemental Content

Support Center